Share this on:
About this iReport
  • Not vetted for CNN

  • Posted December 2, 2013 by

    More from mahendradash

    Breast Cancer medicine discovered


    New breast cancer study results published in The Lancet compare targeted radiotherapy during surgery with ZEISS INTRABEAM to traditional post-surgical radiotherapy treatment Downloads and Links

    5-year results of international TARGIT-A clinical trial support targeted intraoperative radiotherapy (TARGIT) delivered with the ZEISS INTRABEAM as non-inferior to external beam radiotherapy (EBRT) for selected early stage breast cancer patients. RTF Documents
    english (177 KB)

    Further Information
    Medical Technology
    Lancet publication of the results of the TARGIT-A study

    JENA/Germany, 27.11.2013.

    Results of the TARGIT-A clinical trial published in The Lancet

    A new clinical trial for breast cancer, published in The Lancet, one of the world’s leading medical journal, shows that a single fraction of targeted intraoperative radiotherapy (TARGIT) delivered with the INTRABEAM® from ZEISS at time of lumpectomy is non-inferior to traditional external beam radiation (EBRT) delivered over three to six weeks after breast conserving surgery, for a select group of patients.

    “The most important benefit of TARGIT for a woman with breast cancer is that it allows her to complete her entire local treatment at the time of her operation, with lower toxicity to the breast, the heart and other organs. Our research supports the use of TARGIT concurrent with lumpectomy, provided patients are selected carefully, and should allow patients and their clinicians to make a more informed choice about individualizing their treatment, saving time, money, breasts, and lives,” according to Professor Jayant S. Vaidya, FRCS MD, PhD from the international TARGIT investigators group, in the accompanying press release on the Lancet publication of the research study.

    Since 1998, the international TARGIT research group has investigated whether radiotherapy targeted to the tumour bed at the time of surgery can reduce the risk of recurrence in early breast cancer as effectively as the traditional three to six week EBRT.

    Traditionally, whole-breast EBRT is given after lumpectomy (breast conserving surgery) to reduce the risk of recurrence of cancer in the breast and of breast cancer mortality. EBRT typically is given over a course of three to six weeks requiring patients to receive treatment at radiotherapy centers for 20-30 days. In some cases, women suitable for breast conserving surgery, but living far from a radiotherapy center and unable to attend daily post-surgical treatments may even undergo mastectomy as an alternate.

    In the TARGIT approach, during surgery after removal of the tumor, the affected tissue in the tumor bed is irradiated from within the breast using the ZEISS INTRABEAM. The TARGIT study results show that targeted intraoperative radiotherapy delivered with ZEISS INTRABEAM can reduce the risk of recurrence of the cancer as effectively as a traditional 3- to 6-week course of whole breast irradiation in selected women with invasive ductal carcinoma.

    The TARGIT-A trial has been to date the largest multicenter randomized clinical trial for intraoperative radiotherapy (IORT) in the field of partial breast irradiation, with 3451 patients in 33 international centers from Europe, the United States, and Australia. The TARGIT-A trial followed an individualized risk-adapted approach, meaning, that patients who had received TARGIT at the time of surgery showed in the final pathology additional unforeseen risk factors, received supplemental EBRT, which occurred for about 15% of the patients. The 5-year results for local recurrence and the first analysis of overall survival of the TARGIT-A trial have now been reported.

    Comparing TARGIT with EBRT the difference in 5-year local recurrence between the two treatments was less than 2.5% and therefore considered “non-inferior” standard EBRT (daily doses for 3-6 weeks) in treating the cancer. Overall mortality was 3.9% with TARGIT and 5.3% with EBRT, due to fewer deaths from cardiovascular causes and other cancers.

    Based on statistical comparison of breast cancer recurrence, number of deaths and side effects of TARGIT versus EBRT the authors conclude: “TARGIT concurrent with lumpectomy within a risk-adapted approach should be considered as an option for eligible patients with breast cancer carefully selected as per the TARGIT-A trial protocol.”

    “We commend the international TARGIT group pioneered by Professor Jayant Vaidya and Professor Michael Baum for this outstanding research on this new treatment option that can benefit many breast cancer patients. The TARGIT group’s research will further enhance adoption by radiation oncologists and breast surgeons worldwide and will broaden the application of our ZEISS INTRABEAM for this new option in the fight against cancer,” says Dr. Ludwin Monz President and CEO of Carl Zeiss Meditec AG.

    The Lancet publication of the results of the TARGIT-A study can be found at

    Jann Gerrit Ohlendorf
    Director Corporate Communications
    Carl Zeiss Meditec AG
    Phone: +49 3641 220-331
    Fax: +49 3641 220-332

    Alice Swinton
    Group Communications
    Carl Zeiss Meditec, Inc.
    Phone: +1 925 557 4317

    For investors
    Sebastian Frericks
    Investor Relations
    Carl Zeiss Meditec AG
    Phone: +49 3641 220-116

    Number: 0161-2013-ENG OP

    Number of Words: 726
    Number of Characters: 5009


    What do you think of this story?

    Select one of the options below. Your feedback will help tell CNN producers what to do with this iReport. If you'd like, you can explain your choice in the comments below.
    Be and editor! Choose an option below:
      Awesome! Put this on TV! Almost! Needs work. This submission violates iReport's community guidelines.


    Log in to comment

    iReport welcomes a lively discussion, so comments on iReports are not pre-screened before they post. See the iReport community guidelines for details about content that is not welcome on iReport.

    Add your Story Add your Story